Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid versus slow prednisone taper in giant cell arteritis
2018-000344-25Phase 3Active
- Sponsor
- CHU Caen Normandie
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of prednisone in giant cell arteritis (GCA) (2 arms), sponsored by CHU Caen Normandie. Primary endpoint: Complete remission without relapse at week 52. Started Aug 2018; status: active.
02
Drugs
prednisone
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2018-000344-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000344-25.